Americans ages 50 and up now officially eligible to receive 2nd COVID booster
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
It's been a big day for COVID boosters.
Tuesday afternoon, the Centers for Disease Control and Prevention followed the Food and Drug Administration in clearing a new round of Moderna or Pfizer-BioNTech COVID-19 boosters for Americans ages 50 and older, CBS News reports.
Not only did the CDC okay a second booster for older Americans, it also authorized a fourth shot for all adults who received the Johnson & Johnson vaccine and booster at least four months ago, per The Washington Post.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Data released by the CDC shortly before the decision to authorize the second booster showed those who received the single-shot J&J regimen to be at a greater risk of serious hospitalization and illness than those who received the mRNA vaccines, reports the Post. The CDC strongly recommends those populations consider getting a booster dose of either the Pfizer or Moderna vaccine, per The Hill.
The second booster is "especially important for those 65 and older and those 50 and older with underlying medical conditions that increase their risk for severe disease from COVID-19 as they are the most likely to benefit from receiving an additional booster dose at this time," said CDC Director Rochelle Walensky, per The Wall Street Journal.
The FDA and CDC also authorized a second Pfizer booster for immunocompromised individuals ages 12 and up who've received their first COVID booster, and a second Moderna booster for immunocompromised people ages 18 and above, the Journal notes.
The decisions arrive as as the Omicron subvariant BA.2 continues to gain ground in the U.S.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
How Democrats are turning DOJ lemons into partisan lemonadeTODAY’S BIG QUESTION As the Trump administration continues to try — and fail — at indicting its political enemies, Democratic lawmakers have begun seizing the moment for themselves
-
ICE’s new targets post-Minnesota retreatIn the Spotlight Several cities are reportedly on ICE’s list for immigration crackdowns
-
‘Those rights don’t exist to protect criminals’Instant Opinion Opinion, comment and editorials of the day
-
A Nipah virus outbreak in India has brought back Covid-era surveillanceUnder the radar The disease can spread through animals and humans
-
Trump HHS slashes advised child vaccinationsSpeed Read In a widely condemned move, the CDC will now recommend that children get vaccinated against 11 communicable diseases, not 17
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
